Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
13.84
-0.43 (-3.01%)
At close: Apr 28, 2026, 4:00 PM EDT
13.37
-0.47 (-3.43%)
After-hours: Apr 28, 2026, 7:01 PM EDT
Trevi Therapeutics Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for Trevi Therapeutics stock have an average target of 21.55, with a low estimate of 16 and a high estimate of 27. The average target predicts an increase of 55.71% from the current stock price of 13.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Trevi Therapeutics stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 9 | 7 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 13 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $19 | Strong Buy | Maintains | $19 | +37.28% | Apr 17, 2026 |
| Jones Trading | Jones Trading | Strong Buy Maintains $25 → $24 | Strong Buy | Maintains | $25 → $24 | +73.41% | Mar 19, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +30.06% | Mar 18, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $19 | Strong Buy | Maintains | $19 | +37.28% | Mar 18, 2026 |
| Needham | Needham | Strong Buy Maintains $22 → $24 | Strong Buy | Maintains | $22 → $24 | +73.41% | Mar 18, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.46
from -0.32
EPS Next Year
-0.62
from -0.46
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.23 | -0.18 | ||||||
| Avg | -0.46 | -0.62 | ||||||
| Low | -0.59 | -0.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.